Multiple myeloma (MM) is a cancer of the bone marrow made up of plasma cells (a type of antibody-producing white blood cells). Low oxygen levels (called hypoxia) in the bone marrow increases gene expression in MM tumor cells as part of an adaptive survival response. We are targeting this hypoxic response with an experimental drug that blocks expression of these genes to ask if this molecule kills MM in the bone marrow. This is a novel approach to treat MM, an incurable disease.